What’s Going On With Mullen Automotive Stock?

Mullen Automotive Inc (NASDAQ: MULN) shares are trading higher Thursday.

Mullen Automotive Inc (NASDAQ:MULN) shares are trading higher Thursday. The stock initially popped after hours Wednesday and continued higher Thursday after the company said the New York Power Authority (NYPA) began testing its EV Cargo Vans.

What Happened: Mullen announced the launch of a new EV pilot program. The company said NYPA began testing its electric Campus Delivery Utility Vehicles in upstate New York.

“It takes a few organizations to start the buzz of sustainability in each state. We see NYPA as one of the first movers in New York. We look forward to enhancing NYPA and other fleets’ sustainability goals with our various all-electric commercial vehicles,” said John Schwegman, chief commercial officer of Mullen.

NYPA is a power generation and transmission company. It’s the largest state public power organization in the nation. 

After the close on Wednesday Mullen highlighted a recent interview regarding naked short selling with its CEO David Michery in a new regulatory filing. 

Last week, Mullen announced that it retained Christian Attar, in partnership with Warshaw Burstein LLP, to investigate and expose any potential wrongdoing related to a “market manipulation scheme” involving illegal naked short selling.

Mullen previously announced that it was taking affirmative steps to address concerns regarding “extraordinary trading volume and evidence of unusually high levels of failure to deliver on short sales.”

See Also: Why Delta Air Lines Shares Are Rising Today

MULN Price Action: Mullen shares were up 9.19% at 15 cents at the time of publication, according to Benzinga Pro.

Photo: Paul Brennan from Pixabay.

Total
0
Shares
Related Posts
Read More

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of $92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.

INCY

Read More

IPO Previews For The Week

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

CWD

Read More

5 Value Stocks In The Consumer Cyclical Sector

What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

F